Apellis Pharmaceuticals Inc. (APLS) stock soared 9.62% in the pre-market session on Friday, following the release of its fourth-quarter 2024 earnings report.
The biopharmaceutical company reported a net loss of $36.35 million or $0.29 per share for the quarter. However, the losses were offset by strong product revenue of $191.17 million, reflecting robust sales growth for the company's products.
Despite the net loss, investors reacted positively to the revenue growth, driving the stock higher in anticipation of continued momentum. Operating expenses remained high at $238.69 million, but the market seems to be focused on the top-line performance for now.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.